These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27139225)

  • 21. Association between gastrointestinal events and compliance with osteoporosis therapy.
    Siris ES; Fan CS; Yang X; Sajjan S; Sen SS; Modi A
    Bone Rep; 2016 Jun; 4():5-10. PubMed ID: 28326336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of gastrointestinal events on patient-reported outcomes in Asia-Pacific women with osteoporosis: baseline results of the MUSIC OS-AP study.
    Modi A; Ebeling PR; Lee MS; Min YK; Mithal A; Yang X; Baidya S; Sen S; Sajjan S
    Arch Osteoporos; 2017 Dec; 12(1):65. PubMed ID: 28718004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
    Taggart H; Bolognese MA; Lindsay R; Ettinger MP; Mulder H; Josse RG; Roberts A; Zippel H; Adami S; Ernst TF; Stevens KP
    Mayo Clin Proc; 2002 Mar; 77(3):262-70. PubMed ID: 11888030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
    Cotté FE; Mercier F; De Pouvourville G
    Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture.
    Perreault S; Dragomir A; Blais L; Moride Y; Rossignol M; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):248-59. PubMed ID: 18213734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and design of MUSIC OS-EU: an international observational study of the treatment of postmenopausal women for osteoporosis in Europe and Canada.
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Nguyen AM; Keown PA; Leung AT; Sajjan S
    Clin Exp Rheumatol; 2015; 33(4):537-44. PubMed ID: 26146786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the treatment gap among patients with osteoporosis-related fractures in France.
    Fardellone P; Barnieh L; Quignot N; Gusto G; Khachatryan A; Kahangire DA; Worth G; O'Kelly J; Desamericq G
    Arch Osteoporos; 2022 Feb; 17(1):29. PubMed ID: 35113266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in postmenopausal osteoporosis treatment in France during the period 2007-2016: A nationwide claims database analysis.
    Cortet B; Schott AM; Désaméricq G; Chauny JV; Samama P; Emery C; Fagnani F
    Bone; 2022 Jan; 154():116255. PubMed ID: 34763115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone density consequences of initiation and compliance with therapy for osteoporosis.
    Yood RA; Andrade SE; Mazor KM; Fouayzi H; Chan W; Kahler K
    Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1440-5. PubMed ID: 20496423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High rate of non-treatment among osteoporotic women enrolled in a US Medicare plan.
    Yang X; Sajjan S; Modi A
    Curr Med Res Opin; 2016 Nov; 32(11):1849-1856. PubMed ID: 27447285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
    Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
    J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
    Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
    Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec.
    Vanasse A; Dagenais P; Niyonsenga T; Grégoire JP; Courteau J; Hemiari A
    BMC Musculoskelet Disord; 2005 Jun; 6():33. PubMed ID: 15969760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
    Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J
    Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of persistence with weekly bisphosphonates in patients with osteoporosis.
    Jones TJ; Petrella RJ; Crilly R
    J Rheumatol; 2008 Sep; 35(9):1865-73. PubMed ID: 18709688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.
    Overman RA; Gourlay ML; Deal CL; Farley JF; Brookhart MA; Layton JB
    Osteoporos Int; 2015 May; 26(5):1515-24. PubMed ID: 25600474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term persistence with anti-osteoporosis drugs after fracture.
    Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
    Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.